Genome-wide Analysis of Sixteen Chordomas by Comparative Genomic Hybridization and Cytogenetics of the First Human Chordoma Cell Line, U-CH1
Overview
Oncology
Affiliations
Cytogenetic information on chordomas is rudimentary and restricted to GTG-banding analysis of 26 cases worldwide. In this study, we present the chromosomal imbalances detected in a series of 16 chordomas (10 sacrococcyeal, five sphenooccipital, and one spinal) from 13 patients using comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH). On average, 3.2 losses and 4.2 gains were detected per tumor. The most common DNA copy number alterations were losses on chromosomal arms 3p (50%) and 1p (44%). Losses of 3p were detected in five of seven primary chordomas. Therefore, the loss of 3p might be an early event in chordoma genesis. The most common gains involved 7q (69%), 20 (50%), 5q (38%), and 12q (38%). Additionally, we raised the first human chordoma cell line, U-CH1, from a recurrence of a sacral chordoma. U-CH1 and its parent tumor had almost the same CGH profile. According to GTG-banding and multicolor FISH, U-CH1 has the following clonal chromosomal abnormalities: der(1)t(1;22), del(4), +del(5), +del(6), +7, del(9), del(10), +der(20)t(10;20), +21. Thus, the novel permanent human chordoma cell line U-CH1 has chordoma-typical cytogenetic aberrations. Our data suggest that tumor suppressor genes or mismatch repair genes (located at 1p31 and 3p14) and oncogenes (located in 7q36) might be involved in chordoma genesis.
Kantiwal P, Aggarwal A, Yadav S, Gahlot N, Elhence A Am J Neurodegener Dis. 2024; 13(3):13-22.
PMID: 39308697 PMC: 11411203. DOI: 10.62347/EKNJ6411.
Chordoma: Genetics and Contemporary Management.
Desai R, Pelargos P, Dunn I Int J Mol Sci. 2024; 25(11).
PMID: 38892063 PMC: 11172617. DOI: 10.3390/ijms25115877.
Chordoma cells possess bone-dissolving activity at the bone invasion front.
Kawaai K, Oishi Y, Kuroda Y, Tamura R, Toda M, Matsuo K Cell Oncol (Dordr). 2024; 47(5):1663-1677.
PMID: 38652222 PMC: 11466907. DOI: 10.1007/s13402-024-00946-6.
Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line.
Pagani F, Gryzik M, Somenza E, Cominelli M, Balzarini P, Schreiber A J Pers Med. 2023; 13(3).
PMID: 36983607 PMC: 10056194. DOI: 10.3390/jpm13030425.
Passeri T, Dahmani A, Masliah-Planchon J, El Botty R, Courtois L, Vacher S Front Oncol. 2022; 12:960720.
PMID: 36505864 PMC: 9732546. DOI: 10.3389/fonc.2022.960720.